NHS trusts develop local criteria for costly injectable PrEP amid supply limits

Problem-focused framing highlighting resource constraints and equity concerns. The article emphasizes cost burden (£7000 vs £350) and limited access (2000 of 111,000 potential users) to underscore systemic limitations rather than celebrating expansion.

Pharmaceutical pricing power concentrates access to newer treatments among wealthy nations; NHS cost constraints shift decision-making from central policy to fragmented local criteria, potentially creating postcode-based health inequities. Tension between innovation incentives and equitable access.

Similar to early antiretroviral therapy rationing in 1990s-2000s when cost barriers created two-tiered access systems in developed nations, eventually resolved through generic competition and policy pressure.

Patients face restricted access to more effective treatment option based on local criteria rather than clinical need. Creates two-tier system where injectable PrEP availability depends on geographic location and trust resources. Vulnerable populations may be disproportionately excluded due to cost rationing.

NHS faces pressure to either increase injectable PrEP budget allocation, negotiate better pricing with manufacturers, or establish national access criteria to prevent postcode lottery. May trigger debate on cost-effectiveness thresholds for preventive treatments and pharmaceutical pricing negotiations. Could prompt policy review of generic pill accessibility as alternative.